Related Experiment Videos
3-Fluoro-3-deoxy-D-galactose: a new probe for studies on sugar cataract
E F Secchi1, M J Lizak, S Sato
1Laboratory of Ocular Therapeutics, National Eye Institute, National Institutes of Health, Bethesda, MD 20892-1850, USA.
Current Eye Research
|June 18, 1999
Summary
3-fluoro-3-deoxy-D-galactose (3-FDGal) is a promising substrate for monitoring aldose reductase (AR) activity in dog lenses. Its high affinity for AR allows for effective investigation of polyol pathway flux and potential therapeutic interventions.
Area of Science:
- Biochemistry
- Spectroscopy
Background:
- Aldose reductase (AR) activity and polyol pathway flux are crucial in lens metabolism.
- Monitoring AR activity in dog lenses can be achieved using 19F nuclear magnetic resonance (NMR) spectroscopy with fluorinated glucose analogs.
Purpose of the Study:
- To investigate the utilization of 3-fluoro-3-deoxy-D-galactose (3-FDGal) as a substrate by aldose reductase (AR).
- To assess the metabolism of 3-FDGal in intact dog lenses and cultured lens epithelial cells.
- To evaluate 3-FDGal as a potential probe for AR activity using 19F NMR spectroscopy.
Main Methods:
- Incubation of 3-FDGal with purified dog lens AR and galactitol dehydrogenase.
- Culture of dog lenses and lens epithelial cells in 3-FDGal medium with and without the AR inhibitor AL 1576.
- Metabolism analysis using 19F NMR spectroscopy.
Main Results:
- 3-FDGal exhibited higher AR activity than D-galactose, with a 10-fold higher Km.
- Purified AR converted 3-FDGal to 3-fluoro-3-deoxy-D-galactitol, an reaction inhibited by AL 1576.
- Dog lenses metabolized 3-FDGal to both galactitol and galactonic acid, with AL 1576 inhibiting galactitol formation.
- Lens epithelial cells metabolized 3-FDGal to galactitol, and developed vacuoles prevented by AL 1576.
Conclusions:
- 3-FDGal demonstrates high affinity for aldose reductase.
- This fluorinated sugar serves as an excellent probe for studying AR activity in dog lens tissues.
- 3-FDGal metabolism provides insights into polyol pathway flux and potential AR-targeted therapies.